Keywords
Last Name
Institution

TERZAH MARIE HORTON

TitleAssociate Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Pediatrics
Address1102 Bates St., C750
Houston TX 77030
vCardDownload vCard

    Collapse Additional Tools and Researcher Information 
    Collapse Verify Publications

    Collapse Overview 
    Collapse keywords
    leukemia, lymphoma, developmental therapeutics, pediatric oncology, protein homeostasis


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Miller TP, Li Y, Kavcic M, Troxel AB, Huang YS, Sung L, Alonzo TA, Gerbing R, Hall M, Daves MH, Horton TM, Pulsipher MA, Pollard JA, Bagatell R, Seif AE, Fisher BT, Luger S, Gamis AS, Adamson PC, Aplenc R. Accuracy of Adverse Event Ascertainment in Clinical Trials for Pediatric Acute Myeloid Leukemia. J Clin Oncol. 2016 May 1; 34(13):1537-43. PMID: 26884558; PMCID: PMC4872308 [Available on 04/01/17].
    2. Miller TP, Getz KD, Kavcic M, Li Y, Huang YS, Sung L, Alonzo TA, Gerbing R, Daves M, Horton TM, Pulsipher MA, Pollard J, Bagatell R, Seif AE, Fisher BT, Gamis AS, Aplenc R. A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma. 2016 Jul; 57(7):1567-74. PMID: 26727639; PMCID: PMC4899280 [Available on 07/01/16].
    3. Horton TM, Drachtman RA, Chen L, Cole PD, McCarten K, Voss S, Guillerman RP, Buxton A, Howard SC, Hogan SM, Sheehan AM, López-Terrada D, Mrazek MD, Agrawal N, Wu MF, Liu H, De Alarcon PA, Trippet TM, Schwartz CL. A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study. Br J Haematol. 2015 Jul; 170(1):118-22. PMID: 25833390.
      View in: PubMed
    4. Horton T. Yin and yang of glucocorticoid receptors in apoptosis. Blood. 2015 Jan 8; 125(2):209-11. PMID: 25573965.
      View in: PubMed
    5. Niewerth D, Franke NE, Jansen G, Assaraf YG, van Meerloo J, Kirk CJ, Degenhardt J, Anderl J, Schimmer AD, Zweegman S, de Haas V, Horton TM, Kaspers GJ, Cloos J. Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. Haematologica. 2013 Dec; 98(12):1896-904. PMID: 24056819; PMCID: PMC3856965.
    6. Levy AS, Pyke-Grimm KA, Lee DA, Palla SL, Naranjo A, Saulnier Sholler G, Gratias E, Maloney K, Parshankar F, Lee-Scott M, Beierle EA, Gow K, Kim GE, Hunger S, Smith FO, Horton TM. Mentoring in pediatric oncology: a report from the Children's Oncology Group Young Investigator Committee. J Pediatr Hematol Oncol. 2013 Aug; 35(6):456-61. PMID: 23892351; PMCID: PMC3839621.
    7. Horton T, Hunger SP. Children are not large mice. Eur J Haematol. 2013 Jun; 90(6):535. PMID: 23534840.
      View in: PubMed
    8. Hummel TR, Wagner L, Ahern C, Fouladi M, Reid JM, McGovern RM, Ames MM, Gilbertson RJ, Horton T, Ingle AM, Weigel B, Blaney SM. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer. 2013 Sep; 60(9):1452-7. PMID: 23554030; PMCID: PMC4139006.
    9. Kelly KM, Hodgson D, Appel B, Chen L, Cole PD, Horton T, Keller FG. Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2013 Jun; 60(6):972-8. PMID: 23255501.
      View in: PubMed
    10. Muscal JA, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern RM, Reid JM, Ames MM, Espinoza-Delgado I, Weigel BJ, Blaney SM. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916). Pediatr Blood Cancer. 2013 Mar; 60(3):390-5. PMID: 22887890; PMCID: PMC3511610.
    11. Rathore N, Eissa HM, Margolin JF, Liu H, Wu MF, Horton T, Kamdar K, Dreyer Z, Steuber P, Rabin KR, Redell M, Allen CE, McClain KL, Guillerman RP, Bollard CM. Pediatric Hodgkin lymphoma: are we over-scanning our patients? Pediatr Hematol Oncol. 2012 Aug; 29(5):415-23. PMID: 22632168; PMCID: PMC3685486.
    12. Cruz CR, Gerdemann U, Leen AM, Shafer JA, Ku S, Tzou B, Horton TM, Sheehan A, Copeland A, Younes A, Rooney CM, Heslop HE, Bollard CM. Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res. 2011 Nov 15; 17(22):7058-66. PMID: 21908573; PMCID: PMC3218253.
    13. Morrison DJ, Hogan LE, Condos G, Bhatla T, Germino N, Moskowitz NP, Lee L, Bhojwani D, Horton TM, Belitskaya-Levy I, Greenberger LM, Horak ID, Grupp SA, Teachey DT, Raetz EA, Carroll WL. Endogenous knockdown of survivin improves chemotherapeutic response in ALL models. Leukemia. 2012 Feb; 26(2):271-9. PMID: 21844871; PMCID: PMC3833621.
    14. Horton TM, Berg SL. Educational paper. The development of new therapies for pediatric oncology. Eur J Pediatr. 2011 May; 170(5):555-9. PMID: 21190039.
      View in: PubMed
    15. Frugé E, Margolin J, Horton T, Venkateswaran L, Lee D, Yee DL, Mahoney D. Defining and managing career challenges for mid-career and senior stage pediatric hematologist/oncologists. Pediatr Blood Cancer. 2010 Dec 1; 55(6):1180-4. PMID: 20589622.
      View in: PubMed
    16. Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, Winick NJ, Raetz EA, Carroll WL, Arceci RJ, Borowitz MJ, Gaynon PS, Gore L, Jeha S, Maurer BJ, Siegel SE, Biondi A, Kearns PR, Narendran A, Silverman LB, Smith MA, Zwaan CM, Whitlock JA. Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference. Pediatr Blood Cancer. 2010 Jul 1; 54(7):872-8. PMID: 20127846; PMCID: PMC2857540.
    17. Horton TM, Jenkins G, Pati D, Zhang L, Dolan ME, Ribes-Zamora A, Bertuch AA, Blaney SM, Delaney SL, Hegde M, Berg SL. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther. 2009 Aug; 8(8):2232-42. PMID: 19671751; PMCID: PMC3741063.
    18. Jayanthan A, Howard SC, Trippett T, Horton T, Whitlock JA, Daisley L, Lewis V, Narendran A. Targeting the Bcl-2 family of proteins in Hodgkin lymphoma: in vitro cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737. Leuk Lymphoma. 2009 Jul; 50(7):1174-82. PMID: 19557638.
      View in: PubMed
    19. Muscal JA, Thompson PA, Giranda VL, Dayton BD, Bauch J, Horton T, McGuffey L, Nuchtern JG, Dauser RC, Gibson BW, Blaney SM, Su JM. Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemother Pharmacol. 2010 Feb; 65(3):419-25. PMID: 19526240; PMCID: PMC2953793.
    20. Basu D, Zhang N, Panigrahi AK, Horton TM, Pati D. Development and validation of a fluorogenic assay to measure separase enzyme activity. Anal Biochem. 2009 Sep 15; 392(2):133-8. PMID: 19497291; PMCID: PMC2713383.
    21. Thompson PA, Allen CE, Horton T, Jones JY, Vinks AA, McClain KL. Severe neurologic side effects in patients being treated for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2009 May; 52(5):621-5. PMID: 19137570; PMCID: PMC3660724.
    22. Horton TM, Ames MM, Reid JM, Krailo MD, Pendergrass T, Mosher R, Reaman GH, Seibel NL. A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Apr; 50(4):788-92. PMID: 17668866.
      View in: PubMed
    23. Horton TM, Thompson PA, Berg SL, Adamson PC, Ingle AM, Dolan ME, Delaney SM, Hedge M, Weiss HL, Wu MF, Blaney SM. Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol. 2007 Nov 1; 25(31):4922-8. PMID: 17971589.
      View in: PubMed
    24. Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, Adamson PC, Ingle AM, Wright J, Brockman AH, Paton M, Blaney SM. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res. 2007 Mar 1; 13(5):1516-22. PMID: 17332297.
      View in: PubMed
    25. Min DJ, Moskowitz NP, Brownstein C, Lee H, Horton TM, Carroll WL. Diverse pathways mediate chemotherapy-induced cell death in acute lymphoblastic leukemia cell lines. Apoptosis. 2006 Nov; 11(11):1977-86. PMID: 17013760.
      View in: PubMed
    26. Horton TM, Gannavarapu A, Blaney SM, D'Argenio DZ, Plon SE, Berg SL. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006 Jul; 58(1):13-23. PMID: 16292537.
      View in: PubMed
    27. Horton TM, Blaney SM, Langevin AM, Kuhn J, Kamen B, Berg SL, Bernstein M, Weitman S. Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study. Clin Cancer Res. 2005 Mar 1; 11(5):1884-9. PMID: 15756014.
      View in: PubMed
    28. Blaney SM, Bernstein M, Neville K, Ginsberg J, Kitchen B, Horton T, Berg SL, Krailo M, Adamson PC. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol. 2004 Dec 1; 22(23):4804-9. PMID: 15570082.
      View in: PubMed
    29. Suell MN, Horton TM, Dishop MK, Mahoney DH, Olutoye OO, Mueller BU. Outcomes for children with gallbladder abnormalities and sickle cell disease. J Pediatr. 2004 Nov; 145(5):617-21. PMID: 15520760.
      View in: PubMed
    30. Horton TM, Stone JD, Yee D, Dreyer Z, Moake JL, Mahoney DH. Case series of thrombotic thrombocytopenic purpura in children and adolescents. J Pediatr Hematol Oncol. 2003 Apr; 25(4):336-9. PMID: 12679653.
      View in: PubMed
    31. Pease CL, Horton TM, McClain KL, Kaplan SL. Aseptic meningitis in a child after systemic treatment with high dose cytarabine. Pediatr Infect Dis J. 2001 Jan; 20(1):87-9. PMID: 11176579.
      View in: PubMed
    32. Horton TM, Petros JA, Heddi A, Shoffner J, Kaufman AE, Graham SD, Gramlich T, Wallace DC. Novel mitochondrial DNA deletion found in a renal cell carcinoma. Genes Chromosomes Cancer. 1996 Feb; 15(2):95-101. PMID: 8834172.
      View in: PubMed
    33. Horton TM, Graham BH, Corral-Debrinski M, Shoffner JM, Kaufman AE, Beal MF, Wallace DC. Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients. Neurology. 1995 Oct; 45(10):1879-83. PMID: 7477986.
      View in: PubMed
    34. Wallace DC, Shoffner JM, Trounce I, Brown MD, Ballinger SW, Corral-Debrinski M, Horton T, Jun AS, Lott MT. Mitochondrial DNA mutations in human degenerative diseases and aging. Biochim Biophys Acta. 1995 May 24; 1271(1):141-51. PMID: 7599200.
      View in: PubMed
    35. Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, McKee AC, Beal MF, Graham BH, Wallace DC. Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. Genomics. 1994 Sep 15; 23(2):471-6. PMID: 7835898.
      View in: PubMed
    36. Ranheim TS, Shisler J, Horton TM, Wold LJ, Gooding LR, Wold WS. Characterization of mutants within the gene for the adenovirus E3 14.7-kilodalton protein which prevents cytolysis by tumor necrosis factor. J Virol. 1993 Apr; 67(4):2159-67. PMID: 8445725; PMCID: PMC240323.
    37. Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, Beal MF, Wallace DC. Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat Genet. 1992 Dec; 2(4):324-9. PMID: 1303288.
      View in: PubMed
    38. Gooding LR, Ranheim TS, Tollefson AE, Aquino L, Duerksen-Hughes P, Horton TM, Wold WS. The 10,400- and 14,500-dalton proteins encoded by region E3 of adenovirus function together to protect many but not all mouse cell lines against lysis by tumor necrosis factor. J Virol. 1991 Aug; 65(8):4114-23. PMID: 1830111; PMCID: PMC248844.
    39. Gooding LR, Aquino L, Duerksen-Hughes PJ, Day D, Horton TM, Yei SP, Wold WS. The E1B 19,000-molecular-weight protein of group C adenoviruses prevents tumor necrosis factor cytolysis of human cells but not of mouse cells. J Virol. 1991 Jun; 65(6):3083-94. PMID: 1827845; PMCID: PMC240964.
    40. Horton TM, Ranheim TS, Aquino L, Kusher DI, Saha SK, Ware CF, Wold WS, Gooding LR. Adenovirus E3 14.7K protein functions in the absence of other adenovirus proteins to protect transfected cells from tumor necrosis factor cytolysis. J Virol. 1991 May; 65(5):2629-39. PMID: 1850036; PMCID: PMC240621.
    41. Horton TM, Tollefson AE, Wold WS, Gooding LR. A protein serologically and functionally related to the group C E3 14,700-kilodalton protein is found in multiple adenovirus serotypes. J Virol. 1990 Mar; 64(3):1250-5. PMID: 2304142; PMCID: PMC249240.
    HORTON's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _